[CAS NO. 2671128-05-3] FHD-286

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2671128-05-3]

Catalog

HY-144835

Brand

MCE

CAS

2671128-05-3

MDL	-
Molecular Weight	562.66
Molecular Formula	C24H30N6O6S2
SMILES	COC[C@@H](C(NC1=NC(C2=CC=CC(N3C[C@@H](O[C@@H](C3)C)C)=N2)=CS1)=O)NC(C4=CN(C=C4)S(C)(=O)=O)=O

For research use only. We do not sell to patients.

FHD-286 is a BRG1/BRM ATPase inhibitor for the treatment of BAF-related disorders such as acute myeloid leukemia.

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04891757	Foghorn Therapeutics Inc.	Advanced Hematologic Malignancy\|Relapsed Acute Myeloid Leukemia\|Refractory Acute Myeloid Leukemia\|Relapsed Myelodysplastic Syndromes\|Refractory Myelodysplastic Syndromes	June 14, 2021	Phase 1
NCT04879017	Foghorn Therapeutics Inc.	Metastatic Uveal Melanoma	May 17, 2021	Phase 1

Solid

Room temperature in continental US; may vary elsewhere.

In Vitro:

DMSO : 250 mg/mL ( 444.32 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (3.70 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (3.70 mM); Clear solution

* All of the co-solvents are available by MCE.